Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan And MAP Team Up On Inhalable Migraine Treatment

This article was originally published in The Pink Sheet Daily

Executive Summary

Deal with Allergan focuses on detailing to neurologists and pain specialists, leaving MAP free to do other co-promotion deals.
Advertisement

Related Content

Allergan’s Manufacturing Challenges Produce Second Levadex “Complete Response” Letter
Allergan/MAP Planned Merger, Approval Of NuPathe’s Triptan Patch Change U.S. Landscape For Migraine Therapy
Deals of the Week: Allergan/MAP, Actavis/Uteron, Baxter/Ipsen, and More
Allergan Buys MAP To Chart Migraine Franchise Growth
Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential
Allergan Seeks To Extend Botox Use To Overactive Bladder
Allergan Seeks To Extend Botox Use To Overactive Bladder
NuPathe Must Patch Together New Zelrix Launch Timetable After "Complete Response" Letter
Botox For Migraine: How Will The Market Size Up?
Botox For Migraine: How Will The Market Size Up?

Topics

Advertisement
UsernamePublicRestriction

Register

PS071768

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel